查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1985616

能量療法市場：2026-2032年全球市場預測（依產品類型、技術類型、治療領域、給藥途徑及應用分類）

Energy-Based Therapeutics Market by Product Type, Technology Type, Therapeutic Area, Mode, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，能量療法市場價值將達到 78.2 億美元，到 2026 年將成長到 84 億美元，到 2032 年將達到 131.1 億美元，複合年成長率為 7.65%。

主要市場統計數據
基準年 2025 78.2億美元
預計年份：2026年 84億美元
預測年份 2032 131.1億美元
複合年成長率 (%) 7.65%

本書清晰且具有前瞻性地介紹了技術創新、臨床需求和監管變化如何重塑各個專科領域對能量治療方法的採用。

過去十年間，能量治療方法已從小眾治療手段發展成為涵蓋多個臨床專科的基礎平台。設備工程、影像整合和治療流程的創新，拓展了利用聚焦能量進行組織診斷、修復、切除或再生等治療方法的臨床應用範圍。因此，臨床醫生和醫療系統正在重新思考治療流程，以期抓住機遇，縮短治療時間、減少住院時間，並將治療轉移到門診或日間護理機構。

技術融合、服務主導的商業化和供應鏈重組如何從根本上改變能量治療方法的交付和分銷？

該領域正經歷一場變革，其驅動力來自三個相互關聯的因素：技術融合、醫療服務體系重組、實證商業化。醫療設備小型化、影像導引標靶選擇和軟體控制技術的進步，使得治療更加精準、創傷更小。這種融合降低了在門診和社區醫療機構實施的技術門檻，使得以往需要醫院基礎設施的診療程序得以轉移到診所和居家照護環境中。

評估關稅成本壓力對全球能源型醫療設備供應鏈的營運、採購和產品開發的廣泛影響。

政策變化和關稅的引入可能在全球醫療設備供應鏈中造成重大摩擦，而近期關稅措施的累積效應正在重塑採購、製造和定價的動態。醫療設備零件和成品進口成本的上升迫使原始設備製造商 (OEM) 重新評估與供應商的契約，加快替代供應商的認證，並在許多情況下探索建立區域製造地，以降低跨境關稅波動帶來的風險。這些策略轉變發生在對高品質零件和特殊材料持續需求的背景下，使得快速更換供應商變得困難重重。

基於詳細細分的洞察，揭示了技術類型、臨床應用、治療領域、最終用戶、產品類型和交付方式之間的交集，對於制定策略重點至關重要。

了解整個能量治療方法領域中臨床需求、投資和創新集中於哪些細分市場至關重要。從技術角度來看，該市場涵蓋冷凍療法、電刺激療法、高強度聚焦超音波、雷射療法（包括二氧化碳雷射、二極體雷射、鉺YAG雷射和釹：YAG雷射）、磁場療法、微波療法、雙極、單極和多極射頻療法以及超音波。每種技術類別對資本投入、耗材需求和臨床證據的要求各不相同，而雷射和射頻平台由於其高精度和多樣化的施用器生態系統，通常價格較高。

主要全球區域不同的法規結構、商業化路徑和製造生態系統如何創造差異化的機會和營運要求。

區域趨勢對能量治療方法研發公司的監管策略、商業化時間表和生產重點有顯著影響。在美洲，成熟的醫院、門診中心和專科診所生態系統，輔以完善的監管管道和對臨床證據的高度重視，促進了療效已得到證實的先進技術的應用。採購行為傾向於選擇能夠簡化採購流程並提供培訓和服務支援的捆綁式解決方案，而區域生產能力仍集中在已建立的叢集周圍，以支援產品的快速改進。

對成熟企業、專業創新者和跨學科夥伴關係關係如何塑造競爭、差異化和商業化路徑進行現實評估。

能量治療方法領域的競爭動態呈現出多元化的特點，既有成熟的醫療設備製造商，也有專業的系統供應商，還有專注於特定臨床應用和基礎技術的敏捷型Start-Ups。成熟企業通常利用其豐富的產品系列和完善的分銷網路，將設備、耗材和服務合約捆綁銷售；而敏捷的新興參與企業則透過有針對性的臨床證據、更低的資本密集度或創新的臨床工作流程來脫穎而出。隨著企業尋求將療效追蹤和遠端監測融入其價值提案，醫療設備製造商與軟體和分析服務提供者之間的合作也日益普遍。

領導者可以採取切實可行的策略重點和步驟，以降低風險、加速推廣並建立永續的商業性優勢。

產業領導者應優先採取一系列策略行動，在保持廣泛選擇的同時，加速短期內產品的普及應用。首先，企業需要實現供應商網路多元化，並投資於模組化產品架構，以降低關稅和供應鏈風險，同時保持設計柔軟性，從而滿足不同監管市場的需求。其次，將透過可操作的臨床試驗和基於註冊登記的研究來獲取臨床證據，並納入產品開發的早期階段，對於確保獲得有利的報銷和支持基於價值的合約談判至關重要。第三，企業應採用整合式商業模式，將設備銷售、耗材計畫和軟體驅動型服務結合，以創造持續收入並提高客戶維繫。

我們強大的混合方法研究框架，結合專家訪談、監管和臨床證據審查以及情境分析，產生了引人注目的策略見解。

本執行摘要依據的研究整合採用了一種多方面的方法，旨在交叉檢驗定性見解與公開的監管和臨床證據。主要研究包括對臨床醫生、採購經理和經營團隊相關人員進行結構化訪談，以了解實際應用中的促進因素、工作流程和採購標準。次要研究包括同行評審的臨床文獻、監管申報文件、專利趨勢和臨床試驗註冊資訊，以檢驗有關技術性能的說法並識別證據缺口。

策略要點簡明總結，強調以證據主導的商業化、模組化產品設計和彈性的本地部署，以創造永續價值。

總而言之，能量治療方法正處於一個轉折點，技術進步、醫療服務模式的轉變以及不斷變化的商業性需求在此交匯，為改善患者療效和創造新的經營模式提供了重要機會。在此環境下取得成功，取決於能否將嚴謹的臨床證據與靈活的商業策略相結合，以滿足不同的終端用戶需求、適應區域監管環境並兼顧價值鏈的實際情況。能夠提供兼具清晰的經濟和臨床價值，同時又能降低治療複雜性的綜合解決方案的公司，將最有可能實現永續的市場推廣。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：能量療法市場：依產品類型分類

  • 配件和耗材
  • 裝置
  • 服務軟體

第9章：能量療法市場：依技術類型分類

  • 冷凍療法
  • 電刺激
  • 高強度聚焦超音波
  • 雷射
    • 二氧化碳雷射
    • 二極體雷射
  • 磁場療法
  • 微波療法
  • 高頻
    • 雙極
    • 單極
    • 多極
  • 超音波

第10章：能量療法市場：依治療領域分類

  • 循環系統
  • 皮膚科
  • 神經病學
  • 腫瘤學
  • 整形外科

第11章：依實施方法分類的能量療法市場

  • 侵入性
  • 微創
  • 非侵入性

第12章：能量療法市場：按應用領域分類

  • 美麗
    • 塑形
    • 除毛
    • 疤痕治療
    • 活膚
      • 皮膚緊緻
      • 分段式表面置換
      • 光子嫩膚
    • 去除紋身
    • 改善皺紋
  • 循環系統
    • 血管成形術
    • 心律不整的治療
    • 血管外科
  • 腫瘤學
    • 乳癌
    • 肝癌
    • 攝護腺癌
  • 眼科
    • 白內障治療
    • 青光眼治療
    • 視網膜治療
  • 疼痛管理
    • 腰痛
    • 關節疼痛
    • 肌肉骨骼疼痛
  • 物理治療

第13章：能量療法市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：能量療法市集：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 能量療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國能量療法市場

第17章：中國的能量療法市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alcon Vision LLC
  • Alna-Medicalsystem AG
  • AngioDynamics
  • AtriCure, Inc.
  • Bausch Health Companies Inc.
  • BIOLASE, Inc.
  • Biolitec AG
  • Boston Scientific Corporation
  • Bovie Medical Corporation
  • Candela Corporation by Syneron Medical Ltd.
  • Cutera, Inc.
  • Cynosure Inc.
  • Dornier MedTech GmbH
  • EDAP TMS SA
  • Ellex Medical Lasers
  • Hologic, Inc.
  • InMode Ltd.
  • InSightec Ltd.
  • IRIDEX Corporation
  • Johnson and Johnson Vision Care Inc
  • LightMed Corporation
  • Lumenis Ltd.
  • Medtronic plc
  • NIDEk CO. LTD
  • Optos plc
  • PhotoMedex, Inc.
  • Sisram Medical Ltd.
  • Strata Skin Sciences, Inc.
  • Symmetry Surgical Inc.
  • Venus Concept Inc.
Product Code: MRR-BB4648AFF39A

The Energy-Based Therapeutics Market was valued at USD 7.82 billion in 2025 and is projected to grow to USD 8.40 billion in 2026, with a CAGR of 7.65%, reaching USD 13.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.82 billion
Estimated Year [2026] USD 8.40 billion
Forecast Year [2032] USD 13.11 billion
CAGR (%) 7.65%

A clear, forward-looking primer on how technological innovation, clinical demand, and regulatory evolution are reshaping energy-based therapeutic adoption across specialties

The past decade has seen energy-based therapeutics transition from niche procedural tools into foundational platforms across multiple clinical specialties. Innovations in device engineering, imaging integration, and procedure workflows have expanded the clinical footprint of therapies that use focused energy to diagnose, modulate, ablate, or regenerate tissue. As a result, clinicians and health systems are recalibrating treatment algorithms to take advantage of shorter procedure times, reduced hospitalization, and opportunities to shift care toward ambulatory and outpatient settings.

Regulatory pathways and reimbursement environments are evolving in parallel, shaping adoption curves and influencing design priorities for new product entrants. Manufacturers now face a dual imperative: demonstrating robust clinical evidence that substantiates safety and long-term outcomes while also articulating clear economic value propositions for payors and providers. Concurrently, patient expectations for less invasive, more precise, and cosmetically favorable interventions are accelerating demand across aesthetic and therapeutic indications. Taken together, these forces are reorienting investment, partnership, and commercialization strategies across the ecosystem of device developers, service providers, and clinical adopters.

How technological convergence, service-led commercialization, and supply chain realignment are driving a fundamental shift in energy-based therapeutics delivery and adoption

The landscape is undergoing transformative shifts driven by three intersecting vectors: technological convergence, care delivery reorganization, and evidence-based commercialization. Advances in device miniaturization, imaging-guided targeting, and software-enabled controls are enabling treatments that are simultaneously more precise and less invasive. This convergence has lowered technical barriers to adoption in outpatient and ambulatory settings, allowing procedures that once required hospital infrastructure to migrate into clinics and homecare environments.

Simultaneously, the commercialization model is shifting from a purely product-centric approach to integrated solutions that bundle equipment with consumables, digital services, and outcome-monitoring software. Value-based reimbursement models and growing scrutiny on total cost of care are pressuring stakeholders to demonstrate longitudinal patient benefits, not just procedural efficacy. As a result, companies that can pair clinical evidence with service-oriented delivery models and robust real-world data capture are positioned to gain preferential adoption. Finally, external pressures such as supply chain volatility and geopolitical shifts are accelerating near-shoring and supplier diversification strategies, prompting manufacturers to rethink component sourcing and lifecycle management.

Assessing the broad operational, procurement, and product development implications of tariff-driven cost pressures on global energy-based device supply chains

Policy changes and tariff implementations can create material friction across a global medical device supply chain, and the cumulative impact of recent tariff actions is reshaping procurement, manufacturing, and pricing dynamics. Increased import costs for device components and finished goods have prompted original equipment manufacturers to revisit supplier contracts, accelerate qualification of alternative vendors, and in many cases to explore regional manufacturing footprints that reduce exposure to cross-border tariff volatility. These strategic shifts are occurring alongside continued demand for high-quality components and specialized materials, which complicates rapid supplier substitution.

For hospitals, clinics, and ambulatory surgical centers, the direct effect is often higher capital outlay or incremental pricing pressure on consumables, which in turn influences purchasing prioritization and the relative attractiveness of bundled service agreements. Meanwhile, developers face an elevated cost base for R&D and prototyping when critical components become more expensive or less reliably available. Over time, tariff-driven cost pressures can influence product roadmaps by elevating the importance of modularity, component standardization, and software-driven feature differentiation that reduces reliance on high-cost hardware. To mitigate these impacts, strategic responses observed across the industry include diversified supplier networks, near-shore manufacturing investments, and contractual hedging strategies that align stocking policies with forecasted demand and regulatory timelines.

Deep segmentation-driven insights revealing where technology types, clinical applications, therapeutic areas, end users, product types, and modes intersect to shape strategic priorities

Segment-specific dynamics are central to understanding where clinical demand, investment, and innovation are concentrated across the energy-based therapeutics landscape. On the technology front, the market encompasses Cryotherapy, Electrical Stimulation, High Intensity Focused Ultrasound, Laser-including CO2 Laser, Diode Laser, Erbium YAG Laser, and Nd:YAG Laser-Magnetic Field Therapy, Microwave Therapy, Radio Frequency across Bipolar, Monopolar, and Multipolar configurations, and Ultrasound. Each technological family has distinct capital intensity, consumable requirements, and clinical evidence expectations, with lasers and radio frequency platforms often commanding premium pricing due to precision capabilities and diverse applicator ecosystems.

Application-driven segmentation reveals differentiated adoption curves and clinical priorities. Aesthetics applications such as Body Contouring, Hair Removal, Scar Treatment, Skin Rejuvenation-spanning Dermal Tightening, Fractional Resurfacing, and Photofacial-Tattoo Removal, and Wrinkle Reduction are driving rapid commercial uptake in clinic and ambulatory settings where patient demand and procedural revenue are high. Cardiovascular applications including Angioplasty, Arrhythmia Treatment, and Vascular Surgery require rigorous regulatory and clinical validation but offer substantial clinical impact. Oncology applications focused on Breast Cancer, Liver Cancer, and Prostate Cancer demand integration with imaging and multidisciplinary care pathways, while Ophthalmology applications from Cataract Treatment to Glaucoma Treatment and Retinal Therapies emphasize miniaturization and precision. Pain Management covering Back Pain, Joint Pain, Musculoskeletal Pain, and Neuropathic Pain and Physiotherapy fields such as Muscle Stimulation, Rehabilitation, Swelling Reduction, and Wound Healing often favor devices that balance efficacy with low procedural complexity. Surgical indications that include Cardiovascular Surgery, Eye Surgery, Hemostasis, Tissue Ablation, and Tumor Resection place a premium on device reliability and intraoperative ergonomics.

Therapeutic area distinctions-Cardiology, Dermatology, Neurology, Oncology, and Orthopedics-inform clinical trial design and commercial access strategies, while end-user diversity spanning Ambulatory Surgical Centers, Dermatology Clinics, Homecare Settings, Hospitals, and Physiotherapy Centers drives differentiated service and training requirements. Product-level segmentation into Accessories & Consumables, Equipment, and Services & Software underscores the evolving business models where recurring consumables and outcome-monitoring software can create sustained revenue streams. Mode of delivery-Invasive, Minimally Invasive, and Non Invasive-continues to shape regulatory classification, patient recovery expectations, and purchaser criteria. By synthesizing these segmentation layers, stakeholders can prioritize investments where clinical need, reimbursement potential, and operational feasibility converge, tailoring product roadmaps and commercial propositions to the nuances of each segment.

How distinct regulatory frameworks, commercialization pathways, and manufacturing ecosystems across major global regions create differentiated opportunities and execution demands

Regional dynamics significantly influence regulatory strategy, commercialization timelines, and manufacturing priorities for energy-based therapeutic developers. In the Americas, a mature ecosystem of hospitals, ambulatory centers, and specialist clinics is supported by a well-established regulatory pathway and a strong emphasis on clinical evidence, which facilitates adoption for technologies that demonstrate clear outcome improvements. Purchasing behavior tends to favor bundled solutions that simplify procurement and provide training and service support, and regional manufacturing capacity remains concentrated around established clusters that support rapid product iteration.

Across Europe, the Middle East & Africa, regulatory diversity creates both complexity and opportunity. European markets are influenced by harmonized regulatory frameworks and evolving medical device requirements that drive rigorous conformity and post-market surveillance expectations. In many Middle Eastern and African markets, adoption is uneven, with pockets of rapid modernization in urban centers and a growing appetite for devices suited to outpatient or clinic-based care. The Asia-Pacific region exhibits heterogeneity driven by strong manufacturing capabilities, rapidly expanding private healthcare networks, and a growing prevalence of aesthetic and elective procedures. Local R&D centers and contract manufacturers in the region accelerate cost-competitive production, while rising patient demand in urban centers creates sizable opportunities for scalable, lower-cost solutions. Each regional bloc therefore requires distinct go-to-market approaches, regulatory roadmaps, and partnership strategies to align with localized payer models, clinical practice patterns, and supply chain realities.

A pragmatic assessment of how established firms, focused innovators, and cross-disciplinary partnerships are shaping competition, differentiation, and commercialization paths

Competitive dynamics in energy-based therapeutics are characterized by a mix of established medical device firms, specialized system manufacturers, and agile start-ups that often focus on niche clinical applications or enabling technologies. Incumbents frequently leverage broad product portfolios and established distribution networks to bundle equipment with consumables and service contracts, while nimble entrants differentiate on targeted clinical evidence, lower capital intensity, or novel clinical workflows. Partnerships between device makers and software or analytics providers are increasingly prevalent as companies seek to embed outcome tracking and remote monitoring into their value propositions.

Intellectual property, regulatory approvals, and high-quality clinical data remain key barriers to market entry. Therefore, strategic activity often centers on acquiring complementary technologies, forging clinical collaborations, and investing in post-market studies that reinforce safety and long-term efficacy claims. Companies that effectively align product design with end-user operational needs-optimizing ergonomics for surgeons, workflow integration for clinics, and remote support capabilities for homecare-are able to accelerate adoption and create defensible positions. Finally, service-led models and consumable-driven revenue streams are becoming critical levers for sustaining commercial momentum once clinical acceptance is achieved.

Actionable strategic priorities and pragmatic execution levers that leaders can deploy to mitigate risk, accelerate adoption, and build durable commercial advantage

Industry leaders should prioritize a set of strategic actions that preserve optionality while accelerating near-term adoption. First, companies should diversify supplier networks and invest in modular product architectures to reduce tariff and supply chain exposure while preserving design flexibility for different regulatory markets. Second, embedding clinical evidence generation into early product development-through pragmatic trials and registry-based studies-will be essential to secure favorable reimbursement and to support value-based contracting discussions. Third, firms should adopt integrated commercial models that combine equipment sales with consumable programs and software-enabled services to create recurring revenue and improve customer retention.

Additionally, targeted regional strategies will be vital: prioritize high-value clinical indications and geographies with clear regulatory pathways and reimbursement readiness while deploying scalable rollouts in markets with strong outpatient and private clinic penetration. Leaders should also invest in digital ecosystems that enable remote monitoring, outcome measurement, and telehealth-enabled follow-up, thereby enhancing the overall patient experience and strengthening payer conversations. Finally, organizational capability-building-focused on cross-functional regulatory expertise, clinical affairs, and health economics-will accelerate navigation of complex approval pathways and support sustainable market access. By pursuing these coordinated actions, companies can reduce execution risk while maximizing the commercial impact of new product introductions.

A robust mixed-methods research framework combining expert interviews, regulatory and clinical evidence review, and scenario analysis to produce defensible strategic insights

The research synthesis underpinning this executive summary integrates a multi-method approach designed to triangulate qualitative insights with publicly available regulatory and clinical evidence. Primary research included structured interviews with clinicians, procurement leaders, and executive stakeholders to capture real-world adoption drivers, procedural workflows, and purchasing criteria. Secondary analysis encompassed peer-reviewed clinical literature, regulatory filings, patent landscapes, and clinical trial registries to validate technology performance claims and to map evidence gaps.

Data synthesis techniques included thematic analysis of expert interviews, comparative review of regulatory frameworks across major geographies, and scenario-based evaluation of supply chain and tariff impacts. Where direct data were limited, findings were corroborated through cross-validation with clinician advisory panels and simulation of commercial adoption pathways. Quality controls included source triangulation and independent review of clinical interpretations to ensure robustness. Limitations of the methodology are acknowledged, including variability in near-term policy changes and regional reimbursement heterogeneity, and recommendations emphasize adaptive strategies that remain robust across plausible regulatory and market scenarios.

A concise synthesis of strategic takeaways emphasizing evidence-led commercialization, modular product design, and resilient regional execution to capture lasting value

In conclusion, energy-based therapeutics stand at an inflection point where technological advancement, shifting care delivery models, and evolving commercial imperatives converge to create meaningful opportunities for improved patient outcomes and new business models. Success in this environment will hinge on the ability to couple rigorous clinical evidence with flexible commercial strategies that address diverse end-user needs, regional regulatory landscapes, and supply chain realities. Those who can deliver integrated solutions that reduce procedural complexity while demonstrating clear economic and clinical value will be best positioned to capture sustained adoption.

Looking ahead, manufacturers and investors should remain focused on modular product design, evidence-driven market entry, and service-oriented revenue models. Coordinated investments in regional manufacturing resilience, strategic partnerships, and digital health capabilities will mitigate external risks and amplify product differentiation. The path forward rewards strategic patience combined with decisive, evidence-backed market action.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Energy-Based Therapeutics Market, by Product Type

  • 8.1. Accessories & Consumables
  • 8.2. Equipment
  • 8.3. Services & Software

9. Energy-Based Therapeutics Market, by Technology Type

  • 9.1. Cryotherapy
  • 9.2. Electrical Stimulation
  • 9.3. High Intensity Focused Ultrasound
  • 9.4. Laser
    • 9.4.1. CO2 Laser
    • 9.4.2. Diode Laser
  • 9.5. Magnetic Field Therapy
  • 9.6. Microwave Therapy
  • 9.7. Radio Frequency
    • 9.7.1. Bipolar
    • 9.7.2. Monopolar
    • 9.7.3. Multipolar
  • 9.8. Ultrasound

10. Energy-Based Therapeutics Market, by Therapeutic Area

  • 10.1. Cardiology
  • 10.2. Dermatology
  • 10.3. Neurology
  • 10.4. Oncology
  • 10.5. Orthopedics

11. Energy-Based Therapeutics Market, by Mode

  • 11.1. Invasive
  • 11.2. Minimally Invasive
  • 11.3. Non Invasive

12. Energy-Based Therapeutics Market, by Application

  • 12.1. Aesthetics
    • 12.1.1. Body Contouring
    • 12.1.2. Hair Removal
    • 12.1.3. Scar Treatment
    • 12.1.4. Skin Rejuvenation
      • 12.1.4.1. Dermal Tightening
      • 12.1.4.2. Fractional Resurfacing
      • 12.1.4.3. Photofacial
    • 12.1.5. Tattoo Removal
    • 12.1.6. Wrinkle Reduction
  • 12.2. Cardiovascular
    • 12.2.1. Angioplasty
    • 12.2.2. Arrhythmia Treatment
    • 12.2.3. Vascular Surgery
  • 12.3. Oncology
    • 12.3.1. Breast Cancer
    • 12.3.2. Liver Cancer
    • 12.3.3. Prostate Cancer
  • 12.4. Ophthalmology
    • 12.4.1. Cataract Treatment
    • 12.4.2. Glaucoma Treatment
    • 12.4.3. Retinal Therapies
  • 12.5. Pain Management
    • 12.5.1. Back Pain
    • 12.5.2. Joint Pain
    • 12.5.3. Musculoskeletal Pain
  • 12.6. Physiotherapy

13. Energy-Based Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Energy-Based Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Energy-Based Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Energy-Based Therapeutics Market

17. China Energy-Based Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alcon Vision LLC
  • 18.7. Alna-Medicalsystem AG
  • 18.8. AngioDynamics
  • 18.9. AtriCure, Inc.
  • 18.10. Bausch Health Companies Inc.
  • 18.11. BIOLASE, Inc.
  • 18.12. Biolitec AG
  • 18.13. Boston Scientific Corporation
  • 18.14. Bovie Medical Corporation
  • 18.15. Candela Corporation by Syneron Medical Ltd.
  • 18.16. Cutera, Inc.
  • 18.17. Cynosure Inc.
  • 18.18. Dornier MedTech GmbH
  • 18.19. EDAP TMS S.A.
  • 18.20. Ellex Medical Lasers
  • 18.21. Hologic, Inc.
  • 18.22. InMode Ltd.
  • 18.23. InSightec Ltd.
  • 18.24. IRIDEX Corporation
  • 18.25. Johnson and Johnson Vision Care Inc
  • 18.26. LightMed Corporation
  • 18.27. Lumenis Ltd.
  • 18.28. Medtronic plc
  • 18.29. NIDEk CO. LTD
  • 18.30. Optos plc
  • 18.31. PhotoMedex, Inc.
  • 18.32. Sisram Medical Ltd.
  • 18.33. Strata Skin Sciences, Inc.
  • 18.34. Symmetry Surgical Inc.
  • 18.35. Venus Concept Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENERGY-BASED THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ENERGY-BASED THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ENERGY-BASED THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ACCESSORIES & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ACCESSORIES & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ACCESSORIES & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SERVICES & SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SERVICES & SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SERVICES & SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ELECTRICAL STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CO2 LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MAGNETIC FIELD THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MICROWAVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MULTIPOLAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ORTHOPEDICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ORTHOPEDICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BODY CONTOURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY HAIR REMOVAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SCAR TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY DERMAL TIGHTENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY FRACTIONAL RESURFACING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHOTOFACIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TATTOO REMOVAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY WRINKLE REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ARRHYTHMIA TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY VASCULAR SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CATARACT TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GLAUCOMA TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RETINAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY BACK PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY JOINT PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MUSCULOSKELETAL PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PHYSIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 250. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 266. AFRICA ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL ENERGY-BASED THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 294. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. ASEAN ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 296. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 297. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 300. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY RADIO FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 301. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 302. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY MODE, 2018-2032 (USD MILLION)
  • TABLE 303. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 304. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY AESTHETICS, 2018-2032 (USD MILLION)
  • TABLE 305. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY SKIN REJUVENATION, 2018-2032 (USD MILLION)
  • TABLE 306. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, 2018-2032 (USD MILLION)
  • TABLE 307. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. GCC ENERGY-BASED THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION ENERGY-BASED THERAPEUTICS MARKET SIZE,